Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12902000 | 1.00 | NAAA (0.47) | NAAAFFAR1PLA2G2APLA2G5MGLL | |
| SCHEMBL29588752 | 1.00 | NAAA (0.47) | NAAAFFAR1PLA2G2APLA2G5MGLL | |
| SCHEMBL9617124 | 0.95 | SMN1; SMN2 (0.42) | NAAAFFAR1PLA2G2APLA2G5MGLL | |
| SCHEMBL11131834 | 0.76 | NAAA (0.61) | NAAAGPR84CA2L3MBTL1TRPV1 | |
| SCHEMBL31467551 | 0.72 | EPHX1 (0.64) | NAAAL3MBTL1 | |
| SCHEMBL8035784 | 0.72 | EPHX1 (0.40) | NAAAMGLL | |
| SCHEMBL9172752 | 0.71 | PKM (0.60) | NAAAMGLLCA2L3MBTL1 | |
| SCHEMBL9734781 | 0.71 | PKM (0.64) | NAAAMGLLCA2L3MBTL1 | |
| SCHEMBL9169640 | 0.71 | PKM (0.60) | NAAAMGLLCA2L3MBTL1 | |
| SCHEMBL9733961 | 0.71 | PKM (0.64) | NAAAMGLLCA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | NAAA 1399/4885FFAR1 610/4885PLA2G2A 4436/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | NAAA 1449/4885FFAR1 2764/4885PLA2G2A 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.